Cargando…

Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma

BACKGROUND: Many real‐world studies of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are restricted to single centers, limiting the generalizability of their insights. This study aimed to identify important population‐based predictors for survival in patients diagnosed with mPDAC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Kenneth H., Ozer, Muhammet, Cockrum, Paul, Surinach, Andy, Wang, Shu, Chu, Bong Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683530/ https://www.ncbi.nlm.nih.gov/pubmed/34811961 http://dx.doi.org/10.1002/cam4.4415

Ejemplares similares

Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
por: Elias, Rawad, et al.
Publicado: (2022)

Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States
por: Paluri, Ravi, et al.
Publicado: (2022)

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes
por: O'Reilly, Eileen M., et al.
Publicado: (2020)

Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
por: Koeller, Jim, et al.
Publicado: (2020)

The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma
por: George, Ben, et al.
Publicado: (2021)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
por: Croft, Wayne, et al.
Publicado: (2023)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
por: Du, Jiali, et al.
Publicado: (2020)

Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas
por: Fujiwara, Sho, et al.
Publicado: (2019)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
por: Yu, Kenneth H., et al.
Publicado: (2021)

Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma
por: Lau, Allison N, et al.
Publicado: (2020)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
por: Pretta, Andrea, et al.
Publicado: (2022)

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
por: Taieb, Julien, et al.
Publicado: (2023)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
por: Li, Tianjiao, et al.
Publicado: (2019)

Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
por: Varzaru, Bianca, et al.
Publicado: (2023)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

Real‐world implications of nonbiological factors with staging, clinical management, and prognostic prediction in pancreatic ductal adenocarcinoma
por: Wang, Chao, et al.
Publicado: (2022)

Prognostic Significance of Maspin in Pancreatic Ductal Adenocarcinoma
por: Lim, Yun Jeong, et al.
Publicado: (2004)

Prognostic value of γ‐glutamyltransferase‐to‐albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery
por: Li, Shuo, et al.
Publicado: (2019)

Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma
por: Yu, Xiang, et al.
Publicado: (2017)

THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
por: Gimotty, Phyllis A., et al.
Publicado: (2021)

Prognostic Value of VEGF in Human Pancreatic Ductal Adenocarcinoma
por: Lim, Yun Jeong, et al.
Publicado: (2004)

The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma
por: Drexler, Richard, et al.
Publicado: (2020)

Cancer‐associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma
por: Zhang, Aibin, et al.
Publicado: (2017)

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
por: Sinha, Meenal, et al.
Publicado: (2023)

Significance of unphosphorylated and phosphorylated heat shock protein 27 as a prognostic biomarker in pancreatic ductal adenocarcinoma
por: Drexler, Richard, et al.
Publicado: (2020)

Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity
por: Schmuck, Rosa B., et al.
Publicado: (2015)

Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening
por: Cremin, Carol, et al.
Publicado: (2020)

Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
por: Gimotty, Phyllis A., et al.
Publicado: (2022)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data
por: Bengtsson, Axel, et al.
Publicado: (2020)

Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma
por: Hegewisch‐Becker, Susanna, et al.
Publicado: (2018)

FOLFIRINOX or gemcitabine/nab‐paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision‐making in real‐world
por: Marschner, Norbert, et al.
Publicado: (2022)

Elevated glypican‐1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma
por: Lu, Haizhen, et al.
Publicado: (2017)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Development of a prognostic nomogram for metastatic pancreatic ductal adenocarcinoma integrating marital status
por: Ma, Xiang, et al.
Publicado: (2022)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

An Automated Prognostic Model for Pancreatic Ductal Adenocarcinoma
por: Vezakis, Ioannis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_duk1p7cmdjbkd3g65qf2f6nb5v